Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Moderate Buy" by Analysts

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen brokerages that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $56.08.

Several equities research analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Guggenheim reiterated a "buy" rating and issued a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Oppenheimer lowered shares of Arvinas from an "outperform" rating to a "market perform" rating in a research note on Tuesday. Citigroup decreased their price objective on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, March 7th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $8.30 on Wednesday. Arvinas has a fifty-two week low of $7.91 and a fifty-two week high of $46.62. The stock has a market cap of $570.81 million, a price-to-earnings ratio of -3.00 and a beta of 1.95. The firm's 50-day simple moving average is $18.19 and its 200 day simple moving average is $22.33.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the business posted ($2.53) EPS. On average, sell-side analysts predict that Arvinas will post -3.81 EPS for the current year.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,572 shares of company stock worth $695,030. Corporate insiders own 5.23% of the company's stock.

Institutional Investors Weigh In On Arvinas

A number of hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. bought a new stake in Arvinas during the 4th quarter valued at $28,000. KBC Group NV raised its holdings in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after buying an additional 1,255 shares during the last quarter. Quantbot Technologies LP increased its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Arvinas during the 4th quarter valued at $171,000. Finally, Tema Etfs LLC purchased a new position in Arvinas during the 4th quarter valued at $227,000. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.